No Data
No Data
Maxim Group Maintains Virpax Pharmaceuticals(VRPX.US) With Buy Rating, Maintains Target Price $3
Virpax Pharmaceuticals' Promising Outlook: Buy Rating Justified by Strategic Financial Management and Innovative Pain Management Pipeline
Virpax Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 EPS Results.
Express News | Virpax Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 EPS Results
Virpax Pharmaceuticals 2Q Loss/Shr $1.75 >VRPX
Express News | Virpax Pharmaceuticals Q2 2024 GAAP EPS $(1.75) May Not Be Comparable To $(0.61) Estimate
No Data